Stockscreener 앱 받기
0.7676
6.95%
0.0499
시간 외 거래:
.78
0.0124
+1.62%
Pds Biotechnology Corporation 주식(PDSB)의 최신 뉴스
PDS Biotech secures FDA meeting to discuss accelerated approval pathway By Investing.com - Investing.com Nigeria
PDS Biotech secures FDA meeting to discuss accelerated approval pathway - Investing.com
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ('FDA”) - The Manila Times
PDS Biotech (Nasdaq: PDSB) Plans FDA Talk on PFS Endpoint in VERSATILE-003 Trial - Stock Titan
How supply chain issues affect PDS Biotechnology Corporation stockGlobal Markets & Stock Timing and Entry Methods - Newser
Energy Moves: How interest rate cuts could boost PDS Biotechnology Corporation stock2025 Volatility Report & Capital Efficiency Focused Ideas - moha.gov.vn
Adversity is less terrifying than hope: PDS Biotechnology Corporation (PDSB) - Setenews
B. Riley Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $3.00 - Defense World
History Review: How interest rate cuts could boost PDS Biotechnology Corporation stockPortfolio Growth Summary & Precise Buy Zone Tips - BỘ NỘI VỤ
PDS Biotechnology price target lowered to $3 from $5 at B. Riley - Yahoo Finance
B. Riley Securities Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
B. Riley Adjusts Price Target on PDS Biotechnology to $3 From $5, Maintains Buy Rating - MarketScreener
Can PDS Biotechnology Corporation stock reach $100 price targetMarket Performance Report & Growth Focused Investment Plans - newser.com
PDS Biotechnology Shares Face Market Pressure Despite Clinical Promise - Ad-hoc-news.de
What dividend safety score for PDS Biotechnology Corporation stock2025 Market Overview & Real-Time Volume Analysis Alerts - newser.com
Why PDS Biotechnology Corporation stock is recommended by analysts2025 Top Decliners & Growth Focused Stock Reports - newser.com
Earnings visualization tools for PDS Biotechnology CorporationOil Prices & Verified Technical Signals - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedInflation Watch & Breakout Confirmation Alerts - newser.com
Advanced analytics toolkit walkthrough for PDS Biotechnology CorporationCPI Data & Daily Oversold Bounce Ideas - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investorsInflation Watch & Safe Entry Point Identification - newser.com
It makes sense and dollars to buy PDS Biotechnology Corporation (PDSB) stock - Setenews
Is PDS Biotechnology Corporation stock entering bullish territoryJuly 2025 Highlights & Consistent Growth Equity Picks - newser.com
PDS Biotechnology Corp (EU6.DU) stock price, news, quote and history - Yahoo Finance Singapore
Tools to assess PDS Biotechnology Corporation’s risk profilePortfolio Performance Report & Consistent Return Investment Signals - newser.com
Multi factor analysis applied to PDS Biotechnology CorporationWeekly Volume Report & Weekly Chart Analysis and Guides - newser.com
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2025 Earnings Call Transcript - Insider Monkey
Will PDS Biotechnology Corporation stock go up soonWeekly Investment Recap & AI Based Buy and Sell Signals - newser.com
Will PDS Biotechnology Corporation stock reach all time highs in 2025Earnings Growth Summary & Long-Term Safe Return Strategies - newser.com
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Trims Losses And Aims For Accelerated Drug Approval - Finimize
PDS Biotechnology: Promising Trial Results and Financial Update - TipRanks
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 - Investing.com UK
HC Wainwright & Co. Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
PDS Biotechnology Corp (PDSB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Q3 2025 Earnings Report - MarketBeat
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 By Investing.com - Investing.com South Africa
PDS Biotechnology Corporation (PDSB) Q3 FY2025 earnings call transcript - Yahoo Finance
PDS biotechnology Q3 net loss narrows on lower operating expenses - MarketScreener
PDS Biotechnology Corporation Completes VERSATILE-002 Phase 2 Trial, Pursues Expedited Approval for HPV16-Positive Head and Neck Cancer Treatment - Quiver Quantitative
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update - The Manila Times
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[8-K] PDS Biotechnology Corp Reports Material Event | PDSB SEC FilingForm 8-K - Stock Titan
PDS Biotech (Nasdaq: PDSB) to seek accelerated approval in VERSATILE-003 on 6.3-month PFS - Stock Titan
0.93%
1.02%
자본화:
|
볼륨(24시간):